NV
NVNO.US enVVeno Medical Corp
- Market cap
- USD 4.29M
- P/E
- -
- P/B
- 0.21x
- ROE
- -93.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NVNO.US undervalued?
Graham numberThe Graham number of enVVeno Medical Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
enVVeno Medical Corp fundamental analysis
No fundamental analysis for enVVeno Medical Corp yet.
enVVeno Medical Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About enVVeno Medical Corp
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the uppe…
Full company profileenVVeno Medical Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
enVVeno Medical Corp annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 786K | 422K | 187K | 31.2K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -176K | -137K | 187K | 31.2K | -384K | -453K | -525K | -546K | -528K | -489K | - |
| Operating Income | -4.66M | -6.10M | -7.85M | -7.68M | -9.14M | -16.9M | -24.9M | -25.2M | -23.8M | -20.9M | -16.5M |
| EBITDA | -5.38M | -5.73M | -6.05M | -7.23M | -8.75M | -16.1M | -24.1M | -23.0M | -21.3M | -19.0M | -15.9M |
| Net Income | -5.89M | -7.79M | -13.0M | -7.63M | -9.14M | -16.5M | -24.7M | -23.5M | -21.8M | -19.5M | -15.8M |
| EPS | -16,443 | -24,657 | -42,623 | -14,807 | -8,667 | -2,332 | -2,691 | -2,342 | -1,559 | -33 | -23 |
| Balance Sheet | |||||||||||
| Total Assets | 1.78M | 2.21M | 3.56M | 3.43M | 10.5M | 57.7M | 41.7M | 48.6M | 45.0M | 29.6M | 19.5M |
| Total Liabilities | 2.07M | 8.17M | 1.52M | 2.44M | 3.44M | 3.29M | 2.93M | 2.44M | 2.80M | 2.43M | 2.59M |
| Shareholders' Equity | -4.22M | -11.1M | 2.04M | 990K | 7.10M | 54.4M | 38.7M | 46.2M | 42.2M | 27.1M | 16.9M |
| Cash & Short-term Investments | 56.5K | 77.7K | 2.74M | 1.31M | 9.33M | 54.7M | 39.0M | 46.4M | 43.2M | 28.2M | 18.5M |
| Total Debt | 633K | 2.62M | - | 857K | 881K | 2.01M | 1.72M | 1.40M | 1.06M | 700K | 408K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.42M | -4.20M | -6.36M | -5.90M | -7.68M | -11.8M | -15.6M | -18.9M | -16.8M | -15.6M | -13.3M |
| Capital Expenditure | 374K | 10.9K | 12.4K | 364K | 180K | 368K | 115K | 33.0K | 37.0K | 5.00K | 0.00 |
| Free Cash Flow | -3.79M | -4.21M | -6.37M | -6.26M | -7.86M | -12.2M | -15.7M | -18.9M | -16.9M | -15.6M | -13.3M |
| Ratios | |||||||||||
| ROE | - | - | -640.5% | -770.3% | -128.7% | -30.4% | -63.7% | -50.9% | -51.8% | -71.8% | -93.2% |
| ROA | -330.2% | -351.8% | -366.4% | -222.0% | -86.7% | -28.6% | -59.2% | -48.4% | -48.5% | -65.9% | -80.8% |
| Net Profit Margin | -749.0% | -1,845.8% | -6,991.5% | -24,406.7% | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.87x | 0.12x | 0.04x | 0.04x | 0.03x | 0.03x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
enVVeno Medical Corp dividends
enVVeno Medical Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:35 on Jan 20, 2026.
Who owns enVVeno Medical Corp
- Insiders 8.36%
- Institutions 13.01%
- Public & others 78.63%
- Shares outstanding 695K
- Free float 638K
Top funds holding NVNO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 3.30K | 0.47% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 841.00 | 0.12% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 805.00 | 0.12% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 176.00 | 0.03% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 77.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding NVNO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Kingdon Capital Management LLC | 36.2K | 5.21% | 0.00% | Jun 2026 |
| CM Management, LLC | 17.1K | 2.47% | -52.00% | Sep 2026 |
| Vanguard Capital Management, LLC | 6.29K | 0.90% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 5.21K | 0.75% | -0.02% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 2.18K | 0.31% | 0.00% | Jun 2026 |
| Westside Investment Management, Inc. | 1.53K | 0.22% | -4.03% | Jun 2026 |
| Mirae Asset Global Investments (Korea) Co Ltd | 539.00 | 0.08% | 0.00% | Jun 2026 |
| BlackRock Inc | 414.00 | 0.06% | -77.50% | Jun 2026 |
| Tower Research Capital LLC | 331.00 | 0.05% | -38.93% | Jun 2026 |
| Wells Fargo & Co | 114.00 | 0.02% | 0.00% | Jun 2026 |
| Allied Private Wealth LLC | 88.00 | 0.01% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 77.00 | 0.01% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 59.00 | 0.01% | -22.37% | Jun 2026 |
| Advisor Group Holdings, Inc. | 7.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 2.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 1.00 | 0.00% | -99.59% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
enVVeno Medical Corp company profile
- Company name
- enVVeno Medical Corp
- Ticker
- NVNO.US
- Exchange
- USA Stocks
- Listed since
- May 31, 2018
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 33
- Fiscal year end
- December
- Address
- 70 Doppler, Irvine, CA, United States, 92618
- Phone
- 949 261 2900
- Website
- envveno.com
About enVVeno Medical Corp
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
enVVeno Medical Corp management
6- Mr. Robert A. BermanCEO & Director · born 1963
- Ms. Jennifer Bright CPAChief Financial Officer · born 1971
- Dr. Hamed Alavi Ph.D.Senior VP & Chief Technology Officer · born 1984
- Dr. Marc H. Glickman M.D.Senior VP & Chief Medical Officer · born 1949
- Ms. Sandy PriettoVice President of Marketing
- Mr. Avi SharmaSenior Vice President of Clinical, Regulatory & Quality